Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model
about
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesisTargeting the mTOR pathway in hepatocellular carcinoma: current state and future trendsBreast cancer chemoprevention: old and new approachesPhase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis.Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolismUse of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activationInsulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression.Identification of novel tumor antigens with patient-derived immune-selected antibodies.Metformin: a therapeutic opportunity in breast cancer.The transcriptional responsiveness of LKB1 to STAT-mediated signaling is differentially modulated by prolactin in human breast cancer cells.Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.Targeting insulin-like growth factor axis in hepatocellular carcinoma.Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinaLKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cellsFunctional inhibition of UQCRB suppresses angiogenesis in zebrafish.Effects of metformin on retinoblastoma growth in vitro and in vivo.Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv miceMetformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells.The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer.Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin?Metformin prevents tobacco carcinogen--induced lung tumorigenesisAnti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1.Targeting AMPK for cancer prevention and treatment.Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary TumorigenesisDivergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancerTargeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer riskObesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.Anti-angiogenic Effects of Metformin, an AMPK Activator, on Human Umbilical Vein Endothelial Cells and on Granulation Tissue in RatTherapeutic strategies targeting cancer stem cellsInvestigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metforminCell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.AMP-Activated Protein Kinase α 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling.Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice.Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension.Regulation of metformin response by breast cancer associated gene 2.Obesity related hyperinsulinaemia and hyperglycaemia and cancer development.
P2860
Q24614006-9FB302F6-277C-4910-A988-5861B175F5EBQ26830194-A409CC92-3E20-4B01-AEB3-54CAC4629C81Q27693259-9D474518-4C92-4A42-AA73-BAA57D274AC7Q31115487-81A17C2F-6030-42DC-81DC-6C9F5D7F9E89Q33605925-B9C50661-A36B-4F65-A71A-4FE036B677BEQ33635798-9BD75736-A844-4979-A290-36BB70247954Q33645356-3E5CAC60-AE31-4501-B15A-89C6282BCC24Q33688576-859FC1AD-03BC-414E-964C-D91BD1A6BB49Q33707586-2C6145F0-F2D4-431E-88DF-C40DDD10067BQ33733319-639E88F4-A8E8-43C0-A9EE-890988347580Q33783277-ED827DFB-1136-4B03-8A02-0EE7AF1381EFQ33926391-BFCC1E8F-D8DB-4951-9D22-81FAF03BC025Q33951057-689BF0B4-ED13-4B26-8256-F6EF291C30A0Q34113009-E48EBBE1-79A2-4104-87C0-DDD98A02E82DQ34155989-0CAB470C-AC44-4CB1-B4E3-6E86D9725A42Q34330614-4790E41B-6E8F-472E-9D49-82F709D4C33AQ34432841-785515F7-6008-45BD-9A2D-AADDE8780DFCQ34554315-7132282B-966D-4821-A3FE-46F3A52CCA49Q34887704-0D2438AB-4543-4A99-9154-E758EF7AFF37Q34988022-02986D9B-2228-4D55-8AE3-127FFF362C1EQ35124588-4AC8D540-E525-4E53-8150-2554F50C95BDQ35161241-E1345442-2C17-4885-98A0-1E1196D5000EQ35333423-0B40BDA2-73BC-4099-89B8-99DF73C4379BQ35580483-EA57C7D5-4FA1-4926-BD7E-70ABF1E5B2DFQ35781311-8F6FB09B-1A2B-4148-87BE-7BFA8A8E41F1Q36000051-EB714749-9347-450B-981C-D6077683EFC3Q36078840-E64EE863-59AA-4512-A449-9DBE165DDC26Q36500309-9B315DF7-BD0F-49E7-B4FF-64884895EFC3Q36545721-B1FAD36D-78A4-4D51-9196-7D2CE3A66A45Q36582700-7B046162-3EAF-49A2-A3A9-81C9B4F00C52Q36788273-33C051F7-6BAA-49AD-A460-D16CE0179C95Q36821921-67502D4E-D419-40BB-9274-4F33ED7E1286Q36887716-9F5B8D7D-6FF8-4FB5-9BE6-29FA09E17D30Q36905125-1564D752-71E4-47D9-A201-374AD57359CDQ37035849-0056E54A-4E1C-4D7E-ABC1-C8015ED3466BQ37094565-EC5BBE81-7553-46E8-8BF5-F811452AB43FQ37405427-BAA0EF01-7D4F-4FA1-83AE-79DCEDAFF77DQ37434434-9CB6B92A-D677-4BE4-9573-8B90B76717A3Q37448089-C1B57657-1F9E-4DF6-A3B5-F89C849EB33BQ37503147-2FF6BB8C-9746-4C56-8F9E-4A5CD612F517
P2860
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic metformin/AMPK act ...... MDA-MB-435 breast cancer model
@en
Therapeutic metformin/AMPK act ...... DA-MB-435 breast cancer model.
@nl
type
label
Therapeutic metformin/AMPK act ...... MDA-MB-435 breast cancer model
@en
Therapeutic metformin/AMPK act ...... DA-MB-435 breast cancer model.
@nl
prefLabel
Therapeutic metformin/AMPK act ...... MDA-MB-435 breast cancer model
@en
Therapeutic metformin/AMPK act ...... DA-MB-435 breast cancer model.
@nl
P2093
P2860
P1476
Therapeutic metformin/AMPK act ...... MDA-MB-435 breast cancer model
@en
P2093
Frank Vumbaca
Kathryn N Phoenix
Kevin P Claffey
P2860
P2888
P304
P356
10.1007/S10549-008-9916-5
P407
P577
2008-02-07T00:00:00Z